<DOC>
	<DOCNO>NCT01430494</DOCNO>
	<brief_summary>To collect characteristic patient ADPKD across broad population , time well understand disease progression ( sign , symptom outcome ) . Association total kidney volume change measure disease progression determine order identify population increase risk disease progression . The economic quality life impact ADPKD assess . Subjects terminate participation early clinical trial tolvaptan may also follow .</brief_summary>
	<brief_title>Observational Study Patients With Autosomal Dominant Polycystic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<criteria>exist diagnosis ADPKD modifiedRavine criterion Total kidney volume &gt; = 300 cc/m height ultrasound &gt; = 250 cc/m height MRI Current expect ( within next six month ) intervention treatment ADPKD affect kidney volume</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>